Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.

Endo, Mayumi; Roth, Mara Y; Tylee, Tracy S; DeSantis, Anthony; Hirsch, Irl B

Endo, Mayumi; Roth, Mara Y; Tylee, Tracy S; DeSantis, Anthony; Hirsch, Irl B.

Afiliación

Endo M; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA.
Roth MY; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA.
Tylee TS; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA.
DeSantis A; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA.
Hirsch IB; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA.

Diabetes Care ; 46(5): e118, 2023 05 01.

Article en En | MEDLINE | ID: mdl-37185687

Asunto(s)

Diabetes Mellitus; Neoplasias de la Tiroides; Humanos; Receptor del Péptido 1 Similar al Glucagón/agonistas; Neoplasias de la Tiroides/epidemiología; Hipoglucemiantes; Diabetes Mellitus/tratamiento farmacológico; Diabetes Mellitus/epidemiología

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Diabetes Mellitus Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Diabetes Care Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google